Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.03 and traded as low as $4.18. Bolt Biotherapeutics shares last traded at $4.20, with a volume of 8,958 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. Rodman & Renshaw began coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $22.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $34.67.

Bolt Biotherapeutics Stock Up 1.9%

The company has a market cap of $8.22 million, a P/E ratio of -0.26 and a beta of 1.12. The stock has a fifty day moving average price of $4.71 and a two-hundred day moving average price of $5.03. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. On average, research analysts expect that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BOLT. Squarepoint Ops LLC increased its stake in shares of Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after acquiring an additional 2,448 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Bolt Biotherapeutics by 92.2% during the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after acquiring an additional 26,400 shares in the last quarter. Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics in the 3rd quarter worth about $89,000. Shay Capital LLC bought a new position in Bolt Biotherapeutics in the 3rd quarter worth about $85,000. Finally, T3 Companies LLC bought a new stake in Bolt Biotherapeutics during the 4th quarter valued at about $208,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.